BACKGROUND: Current research is inconclusive regarding the relation between alcohol consumption and prostate cancer risk. In this study, the authors examined the associations of total alcohol, type of alcoholic beverage, and drinking pattern with the risk of total, low-grade, and high-grade prostate cancer. METHODS: Data for this study came from the 2129 participants in the Prostate Cancer Prevention Trial (PCPT) who had cancer detected during the 7-year trial and 8791 men who were determined by biopsy to be free of cancer at the trial end. Poisson regression was used to calculate relative risks (RRs) and 95% confidence intervals (95% CIs) for associations of alcohol intake with prostate cancer risk. RESULTS: Associations of drinking with high-grade disease did not differ by treatment arm. In combined arms, heavy alcohol consumption (> or =50 g of alcohol daily) and regular heavy drinking (> or =4 drinks daily on > or =5 days per week) were associated with increased risks of high-grade prostate cancer (RR, 2.01 [95% CI, 1.33-3.05] and 2.17 [95% CI, 1.42-3.30], respectively); less heavy drinking was not associated with risk. Associations of drinking with low-grade cancer differed by treatment arm. In the placebo arm, there was no association of drinking with risk of low-grade cancer. In the finasteride arm, drinking > or =50 g of alcohol daily was associated with an increased risk of low-grade disease (RR, 1.89; 95% CI, 1.39-2.56); this finding was because of a 43% reduction in the risk of low-grade cancer attributable to finasteride treatment in men who drank <50 g of alcohol daily and the lack of an effect of finasteride in men who drank > or =50 g of alcohol daily (P(interaction) = .03). CONCLUSIONS: Heavy, daily drinking increased the risk of high-grade prostate cancer. Heavy drinking made finasteride ineffective for reducing prostate cancer risk.
BACKGROUND: Current research is inconclusive regarding the relation between alcohol consumption and prostate cancer risk. In this study, the authors examined the associations of total alcohol, type of alcoholic beverage, and drinking pattern with the risk of total, low-grade, and high-grade prostate cancer. METHODS: Data for this study came from the 2129 participants in the Prostate Cancer Prevention Trial (PCPT) who had cancer detected during the 7-year trial and 8791 men who were determined by biopsy to be free of cancer at the trial end. Poisson regression was used to calculate relative risks (RRs) and 95% confidence intervals (95% CIs) for associations of alcohol intake with prostate cancer risk. RESULTS: Associations of drinking with high-grade disease did not differ by treatment arm. In combined arms, heavy alcohol consumption (> or =50 g of alcohol daily) and regular heavy drinking (> or =4 drinks daily on > or =5 days per week) were associated with increased risks of high-grade prostate cancer (RR, 2.01 [95% CI, 1.33-3.05] and 2.17 [95% CI, 1.42-3.30], respectively); less heavy drinking was not associated with risk. Associations of drinking with low-grade cancer differed by treatment arm. In the placebo arm, there was no association of drinking with risk of low-grade cancer. In the finasteride arm, drinking > or =50 g of alcohol daily was associated with an increased risk of low-grade disease (RR, 1.89; 95% CI, 1.39-2.56); this finding was because of a 43% reduction in the risk of low-grade cancer attributable to finasteride treatment in men who drank <50 g of alcohol daily and the lack of an effect of finasteride in men who drank > or =50 g of alcohol daily (P(interaction) = .03). CONCLUSIONS: Heavy, daily drinking increased the risk of high-grade prostate cancer. Heavy drinking made finasteride ineffective for reducing prostate cancer risk.
Authors: R A Breslow; L Wideroff; B I Graubard; D Erwin; M E Reichman; R G Ziegler; R Ballard-Barbash Journal: Ann Epidemiol Date: 1999-05 Impact factor: 3.797
Authors: Ellen T Chang; Maria Hedelin; Hans-Olov Adami; Henrik Grönberg; Katarina A Bälter Journal: Cancer Causes Control Date: 2005-04 Impact factor: 2.506
Authors: S O Andersson; J Baron; R Bergström; C Lindgren; A Wolk; H O Adami Journal: Cancer Epidemiol Biomarkers Prev Date: 1996-07 Impact factor: 4.254
Authors: Maddalena Barba; Susan E McCann; Holger J Schünemann; Saverio Stranges; Barbara Fuhrman; Sabino De Placido; Giuseppe Carruba; Jo L Freudenheim; Maurizio Trevisan; Marcia Russell; Tom Nochajski; Paola Muti Journal: Nutr J Date: 2004-12-09 Impact factor: 3.271
Authors: Barbra A Dickerman; Sarah Coseo Markt; Markku Koskenvuo; Eero Pukkala; Lorelei A Mucci; Jaakko Kaprio Journal: Cancer Causes Control Date: 2016-06-28 Impact factor: 2.506
Authors: Jeannette M Schenk; Alan R Kristal; Kathryn B Arnold; Catherine M Tangen; Marian L Neuhouser; Daniel W Lin; Emily White; Ian M Thompson Journal: Am J Epidemiol Date: 2011-05-03 Impact factor: 4.897
Authors: Jeannette M Schenk; Cathee A Till; Catherine M Tangen; Phyllis J Goodman; Xiaoling Song; Kathleen C Torkko; Alan R Kristal; Ulrike Peters; Marian L Neuhouser Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-08 Impact factor: 4.254